NARA Discovery
Article Details
← Back to Search Results
Journal Article

The impact of fluconazole use on the fungal and bacterial microbiomes in recurrent Vulvovaginal Candidiasis (RVVC): a pilot study of vaginal and gastrointestinal site interplay

Moira Bradfield Strydom; Tiffanie M. Nelson; Sohil Khan; Ramesh L. Walpola; Robert S. Ware; Evelin Tiralongo
European Journal of Clinical Microbiology & Infectious Diseases · Vol. 44, Issue 2 · pp. 285-301 · 2025

Abstract

Purpose Recurrent Vulvovaginal Candidiasis (RVVC) is a problematic clinical condition for which fluconazole treatment is commonly prescribed. This study investigated the interkingdom vaginal and gastrointestinal microbiomes of RVVC patients who use fluconazole intermittently or as longer-term maintenance therapy for symptom management and compared them to healthy controls. Methods Vaginal swabs and fecal samples were collected. A novel interkingdom analysis was performed using 16 S rRNA and ITS1 gene sequencing to compare the diversity and taxonomic composition of vaginal microbiome (VMB) and gastrointestinal microbiome (GIMB). Results Twenty-seven women participated: 10 intermittent users and healthy controls and 7 maintenance therapy. The study revealed that microbiomes of fluconazole users do not differ in diversity metrics from healthy controls. RVVC patients using intermittent fluconazole displayed a higher abundance of vaginal C. albicans than healthy controls. Candida species pairings were not commonly observed between sites in individuals and, as such a fecal reservoir is unlikely to be implicated in recurrent symptomatology. In many of the RVVC non- Candida fungal spp. were identified in the vaginal microbiome. Users of fluconazole displayed elevations of the CST-I (Community State Type 1) associated bacterium L. crispatus. All participants displaying vaginal Candida spp. belonged to either bacterial CST-I or CST-III (Community State Type 3- L. iners associated). Conclusion To our knowledge, this is the first study to compare the interkingdom VMB-GIMB of women with RVVC using oral fluconazole. As fluconazole users in this study represent a typical RVVC population, trends observed in microbial abundance require further analysis to establish fluconazole’s long-term microbiome safety. Examining the microbiome at both sites adds to the current understanding of microbial associated with the condition.

Bibliographic Information

JournalEuropean Journal of Clinical Microbiology & Infectious Diseases
PublisherSpringer
Publication Date2025-02-01
Publication Year2025
Volume44
Issue2
Pages285-301
Document TypeJournal Article
Print ISSN0934-9723
eISSN1435-4373
DOI10.1007/s10096-024-04999-1

Access Information

NARA Access Coverage1982-01-01~Current
Journal Homepagehttps://www.springer.com/journal/10096
Publisher PageOpen Publisher Page
Full-text access depends on NARA's subscribed coverage and institutional access.